Dicot initiates toxicology studies before applying for clinical trials

Press release: Uppsala, January 29, 2021. Potency agent drug developer Dicot launches a toxicology program for the drug candidate LIB-01. The program runs until the autumn and will form the basis for an application for clinical trials on humans.

In accordance with Dicot's development plan, the company will move on to toxicological studies that are expected to be completed in the autumn of 2021. It is toxicology that determines the extent of possible side effects in the body. The studies aim at evaluating the extent to which the active substance in the drug candidate LIB-01 (formerly Libiguin) is toxic to the user. Since all chemicals are considered to have a certain toxic effect if the dose is high enough, the study also establishes the maximum dose that can be used in future studies.

Dicot's toxicological program consists of one study in rodents and one in non-rodents, which is a requirement of the medical products agencies. Rat and dog are the most common animal models in this type of study.

The program began in December with a fourteen-day study - a so-called dose range finding study - in rats. Analysis of the results is currently underway. It will be followed by the same type of study in dogs, thereafter by experiments in both animal models with dosing for 28 days. The studies are carried out in collaboration with certified Clinical Research Organizations (CRO) with extensive experience of regulatory studies and accredited to perform these according to the standard Good Laboratory Practice.

Studies of a drug candidate's toxicity constitute a necessary and important part of the authorities' assessment prior to clinical trials and will form the basis for Dicot's application to perform clinical trials in healthy volunteers.

"In early preclinical studies, we have noted that side effects appear to be very limited. My hope is that the results from our toxicological program will provide answers that confirm this ", Göran Beijer, CEO of Dicot, comments.

For further information, please contact:
Göran Beijer, CEO
Tel: +46 (0) 706 63 60 09
E-mail: [email protected]

About Dicot AB                                                                     

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion.

Research and development is conducted under own auspices up to phase 1 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit: www.dicot.se

Nerladdningsbara filer

European Association of Urology har valt ut Dicots studieresultat för presentation

Uppsala, 21 december 2021. Läkemedelsföretaget Dicot meddelar att resultaten som visar effekt av Dicots läkemedelskandidat i en sjukdomsmodell kommer att presenteras på European Association of Urology's (EAU) årliga kongress 2022, i Amsterdam.


European Association of Urology has selected Dicot's study result to be presented

Uppsala, December 21, 2021. The pharmaceutical company Dicot announces that the results showing effect of Dicot's drug candidate in a disease animal model will be presented at the European Association of Urology's (EAU) annual congress 2022 in Amsterdam.


Dicots studieresultat presenteras på ledande vetenskaplig kongress

Pressmeddelande: Uppsala, 6 december 2021. Läkemedelsföretaget Dicot meddelar att resultaten som visar effekten av Dicots läkemedelskandidat kommer att presenteras på European Society for Sexual Medicine's (ESSM) årliga kongress i Rotterdam i februari 2022.


Dicot's study results to be presented at leading scientific congress

Press release: Uppsala, December 6, 2021. The pharmaceutical company Dicot announces that the results of Dicot's drug candidate will be presented at the European Society for Sexual Medicine's (ESSM) annual congress in Rotterdam in February 2022.


Dicots potensläkemedelskandidat visar effekt och lång duration även vid låg dosering

Pressmeddelande: Uppsala, 2 december 2021. Dicots senaste djurstudie visar att läkemedelskandidaten LIB-01 har effekt även vid en låg dos samt att 7 dagars duration av effekt på erektil funktion har konfirmerats. Det ger goda förutsättningar inför kommande kliniska studier på människa.


Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose

Press release: Uppsala, December 2, 2021. Dicot's latest animal study demonstrates effect of the drug candidate LIB-01 even at low dose and the 7-day duration of effect on erectile function was confirmed, which provides solid ground for coming clinical studies in humans.


Information om valberedning i Dicot AB

Uppsala, 22 november 2021. Enligt det beslut om valberedningen som fattades vid årsstämman i Dicot AB den 25 maj 2021 ska valberedningen inför årsstämman den 24 maj 2022 bestå av tre ledamöter representerande de tre största aktieägarna per den sista september 2021. För det fall någon av de tre största aktieägarna inte önskar utse en ledamot av valberedningen ska den fjärde största aktieägaren tillfrågas (och så vidare) intill dess att valberedningen består av tre ledamöter.


Dicots företrädesemission är registrerad - omvandling av BTU till aktier och teckningsoptioner samt upptagande till handel av teckningsoptioner

Uppsala, 22 november 2021. Dicot AB (publ) ("Dicot" eller "Bolaget") har genomfört en företrädesemission av units om cirka 25,3 MSEK, som avslutades den 27 oktober 2021 ("Företrädesemissionen"). Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is registered - paid subscription units (BTU) are converted to shares and warrants, and trading of warrants commences

Uppsala, November 22, 2021. Dicot AB (publ) ("Dicot" or the "Company") has carried out a rights issue of units to an amount of approximately MSEK 25.3 ("the Rights Issue"). The Rights Issue was completed on October 27, 2021. The Rights Issue was subscribed to 97.9 percent. Through the Rights Issue, the Company obtains approximately MSEK 24.7 before issue costs.


Dicot AB Delårsrapport januari - september 2021

Pressmeddelande: Uppsala, 18 november 2021. Dicot ABs (publ) delårsrapport för januari - september 2021 finns nu tillgänglig på bolagets hemsida www.dicot.se.


Summary of Interim Report January - September 2021, Dicot AB

Press release: Uppsala, November 18, 2021. A summary of the Interim report January - September 2021, for Dicot AB (publ) is now available on the company website www.dicot.se 


Dicots företrädesemission tecknades till cirka 98 procent

Uppsala, 1 november 2021. Företrädesemissionen om 25,3 MSEK som offentliggjordes den 8 september 2021 och som godkändes av extra bolagsstämman den 6 oktober 2021 ("Företrädesemissionen") i Dicot AB (publ) ("Dicot" eller "Bolaget") blev nästan fulltecknad. Företrädesemissionen tecknades till totalt 97,9 procent. Genom Företrädesemissionen tillförs Bolaget cirka 24,7 MSEK före emissionskostnader.


Dicot's rights issue is subscribed with approx. 98 percent

Uppsala, November 1, 2021. The rights issue of SEK 25.3 million which was disclosed on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue")  in Dicot AB (publ) ("Dicot" or the "Company") has almost been fully subscribed. The Rights Issue was subscribed to 97.9percent. Through the Rights Issue, the Company obtains approximately SEK 24.7 million before issue costs.


Med anledning av positiva studieresultat offentliggör Dicot tilläggsprospekt

Pressmeddelande: Uppsala, 20 oktober 2021. Med anledning av att Dicot AB ("Dicot" eller "Bolaget") den 14 oktober 2021 offentliggjorde positiva resultat från en avslutad studie under den pågående teckningsperioden i Bolagets förestående företrädesemissionen av units har Bolaget nu upprättat ett tilläggsprospekt ("Tilläggsprospektet") till det EU-tillväxtprospekt som godkändes och registrerades av Finansinspektionen den 8 oktober 2021 ("Prospektet"). Tilläggsprospektet - som godkändes av Finansinspektionen idag den 20 oktober 2021 - är en del av och ska läsas tillsammans med Prospektet.


Due to positive study results Dicot publishes a supplement prospectus

Press release: Uppsala, October 20, 2021. On October 14, 2021 Dicot AB ("Dicot" or the "Company") published positive results from a completed study. Since that publication was made during the subscription period in the ongoing unit rights issue the Company has now established a supplement prospectus (the "Supplement") to the EU growth prospectus related to the invitation to subscribe for units in Dicot with preferential rights which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (''SFSA'') on October 8, 2021 (hereinafter, the "Prospectus"). The Supplement - which was approved by the Swedish Financial Supervisory Authority today October 20, 2021 - forms a part of the Prospectus and shall in all respects be read together with the Prospectus.



Studie av djur med diabetes visar på effekt hos Dicots läkemedelskandidat

Pressmeddelande: Uppsala, 14 oktober 2021. Potensläkemedelsutvecklaren Dicot har precis avslutat en studie på råttor med diabetes och bevisad erektil dysfunktion. Bolagets läkemedelskandidat demonstrerade signifikant förbättrad erektion jämfört med kontrollgruppen.


Study of animals with diabetes shows effect in Dicot's drug candidate

Press release: Uppsala, October 14, 2021. Potency drug developer Dicot has just completed a study on rats with diabetes and proven erectile dysfunction. The company's drug candidate demonstrated significantly improved erections compared to vehicle.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted